These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 36672689)

  • 1. Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma.
    Franczyk B; Rysz J; Ławiński J; Ciałkowska-Rysz A; Gluba-Brzózka A
    Biomedicines; 2023 Jan; 11(1):. PubMed ID: 36672689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials.
    Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prospects of pazopanib in advanced renal cell carcinoma.
    Gupta S; Spiess PE
    Ther Adv Urol; 2013 Oct; 5(5):223-32. PubMed ID: 24082917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.
    Keisner SV; Shah SR
    Drugs; 2011 Mar; 71(4):443-54. PubMed ID: 21395357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiotherapy and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors in Renal Cancer.
    Fiore M; D Apos Angelillo RM; Greco C; Fioroni I; Ippolito E; Santini D; Ramella S
    Chemotherapy; 2018 Mar; 63(2):83-89. PubMed ID: 29554654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
    Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
    Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical use of vascular endothelial growth factor receptor inhibitors for the treatment of renal cell carcinoma.
    Li W; Feng C; Di W; Hong S; Chen H; Ejaz M; Yang Y; Xu TR
    Eur J Med Chem; 2020 Aug; 200():112482. PubMed ID: 32492594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
    Koo DH; Park I; Ahn JH; Lee DH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Lee JL
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):339-47. PubMed ID: 26687171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma.
    Lai Y; Zhao Z; Zeng T; Liang X; Chen D; Duan X; Zeng G; Wu W
    Cancer Cell Int; 2018; 18():31. PubMed ID: 29527128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal management of metastatic renal cell carcinoma: current status.
    Escudier B; Albiges L; Sonpavde G
    Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
    Vano YA; Elaidi R; Bennamoun M; Chevreau C; Borchiellini D; Pannier D; Maillet D; Gross-Goupil M; Tournigand C; Laguerre B; Barthélémy P; Coquan E; Gravis G; Houede N; Cancel M; Huillard O; Beuzeboc P; Fournier L; Méjean A; Cathelineau X; Doumerc N; Paparel P; Bernhard JC; de la Taille A; Bensalah K; Tricard T; Waeckel T; Pignot G; Braychenko E; Caruso S; Sun CM; Verkarre V; Lacroix G; Moreira M; Meylan M; Bougouïn A; Phan L; Thibault-Carpentier C; Zucman-Rossi J; Fridman WH; Sautès-Fridman C; Oudard S
    Lancet Oncol; 2022 May; 23(5):612-624. PubMed ID: 35390339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma.
    Xu W; Puligandla M; Manola J; Bullock AJ; Tamasauskas D; McDermott DF; Atkins MB; Haas NB; Flaherty K; Uzzo RG; Dutcher JP; DiPaola RS; Bhatt RS
    Clin Cancer Res; 2019 Oct; 25(20):6098-6106. PubMed ID: 31471309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relationship between treatment-related hypertension and therapeutic efficacy of vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell carcinoma].
    Song Y; Du CX; Zhang W; Sun YK; Yang L; Cui CX; Chi Y; Zhou AP; Wang JW; Sun Y
    Zhonghua Zhong Liu Za Zhi; 2016 Sep; 38(9):698-702. PubMed ID: 27647404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.
    Ciccarese C; Iacovelli R; Brunelli M; Massari F; Bimbatti D; Fantinel E; De Marco V; Porcaro AB; Martignoni G; Artibani W; Tortora G
    Eur J Cancer; 2017 Sep; 83():237-246. PubMed ID: 28756136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors.
    Graham J; Shah AY; Wells JC; McKay RR; Vaishampayan U; Hansen A; Donskov F; Bjarnason GA; Beuselinck B; De Velasco G; Iafolla M; Duh MS; Huynh L; Chang R; Zanotti G; Ramaswamy K; Choueiri TK; Tannir NM; Heng DYC
    Eur Urol Oncol; 2021 Feb; 4(1):102-111. PubMed ID: 31786162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
    Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
    Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management.
    Vallerio P; Orenti A; Tosi F; Maistrello M; Palazzini M; Cingarlini S; Colombo P; Bertuzzi M; Spina F; Amatu A; Lombardo R; Prata I; Scaglione F; Vighi GD; Severgnini B; Siena S; Giannattasio C; Boracchi P; Sartore-Bianchi A
    ESMO Open; 2022 Feb; 7(1):100338. PubMed ID: 34920290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging oral VEGF inhibitors for the treatment of renal cell carcinoma.
    Stitzlein L; Rao P; Dudley R
    Expert Opin Investig Drugs; 2019 Feb; 28(2):121-130. PubMed ID: 30572736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
    Cabebe E; Wakelee H
    Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study.
    Goldman A; Bomze D; Dankner R; Fourey D; Boursi B; Arad M; Maor E
    Target Oncol; 2021 Jul; 16(4):471-483. PubMed ID: 33970401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.